Asia On The Move: Personnel News From Shanghai Pharma, Daiichi Sankyo, Merck Serono, Mindray, GSK
This article was originally published in PharmAsia News
Shanghai Pharma has a new CEO after a large shakeup, and GSK appoints an interim head of discovery in China after Nature Medicine fallout. Mindray returns to co-CEO model, and personnel changes occur at Astellas, Merck Serono, Daiichi Sankyo and RDPAC.
You may also be interested in...
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?
Special guest, Citeline's Annie Siu, discusses the recent ESMO meeting and Jiangsu Hengrui and BeiGene's PD-1 data for hepatocellular carcinoma in this latest episode of the Chinese-language China Biotech podcast.
China’s Negative List for Foreign Investment explicitly bars “investment and application in human stem cells, genetic diagnosis, and treatment technologies.” But whether that applies to foreign pharma firms developing such modalities in the country remains unclear.